[The pharmacokinetic characteristics of theophylline in patients with chronic nonspecific intestinal diseases in relation to its routes of administration into the gastrointestinal tract].
Theophylline pharmacokinetics was investigated upon introduction of euphylline (0.15 g) at four levels of gastrointestinal tract: orally (20 patients), into the jejunum (15 patients) at enterogastroduodenoscopy, in the ileocecal area (8 patients) at colonoscopy and rectally (9 patients). Absorption speed depended on the variant of the gastrointestinal introduction rather than on the variant of chronic nonspecific intestinal disease, and appeared maximal in the drug introduction into the jejunum. Concentration and area under curve became maximal in minor participation of the liver in primary capture and biotransformation of theophylline. Reduced theophylline doses are recommended in lower hepatic metabolism of the drug, in hepatic hypofunction, in rectal route of administration.
Kukes
V G
VG
Fazylov
A V
AV
Kirkin
B V
BV
Kurapov
A P
AP
Blinov
I L
IL
D000285:Administration, Rectal; D000293:Adolescent; D000328:Adult; D000368:Aged; D000628:Aminophylline / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D002908:Chronic Disease; D004064:Digestive System / Q000378:metabolism*; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D007410:Intestinal Diseases / Q000188:drug therapy / Q000378:metabolism*; D008173:Lung Diseases, Obstructive / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012996:Solutions; D013607:Tablets; D013806:Theophylline / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D013997:Time Factors
D012996:Solutions; D013607:Tablets; D000628:Aminophylline; D013806:Theophylline